|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
JP2703764B2
(ja)
|
1986-04-28 |
1998-01-26 |
シータス オンコロジー コーポレイション |
補体成分C5aに対するモノクローナル抗体
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
US5244800A
(en)
|
1990-04-27 |
1993-09-14 |
The Uab Research Foundation |
Crystals of human complement factor d that are triclinic
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
WO1993000109A1
(en)
|
1991-06-28 |
1993-01-07 |
Genentech, Inc. |
Method of stimulating immune response using growth hormone
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US5456909A
(en)
|
1992-08-07 |
1995-10-10 |
T Cell Sciences, Inc. |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
|
EP0656789B1
(en)
|
1992-08-21 |
1997-12-17 |
Genentech, Inc. |
Method for treating a lfa-1-mediated disorder
|
|
AU6048294A
(en)
|
1992-11-25 |
1994-06-22 |
Amgen Boulder Inc. |
Modified insulin-like growth factors
|
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
|
JPH08508296A
(ja)
|
1993-04-07 |
1996-09-03 |
アムジエン・ブルダー・インコーポレーテッド |
インシュリン様成長因子結合タンパク質の使用方法
|
|
US5856300A
(en)
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
|
US5627264A
(en)
|
1994-03-03 |
1997-05-06 |
Alexion Pharmaceuticals, Inc. |
Chimeric complement inhibitor proteins
|
|
DE69533921T2
(de)
|
1994-03-23 |
2005-12-01 |
Alexion Pharmaceuticals, Inc., New Haven |
Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
|
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
|
US5919623A
(en)
|
1994-04-27 |
1999-07-06 |
St. James's And Seacroft University Hospitals Nhs Trust |
Nucleic acid mutation assays
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
|
US5897475A
(en)
|
1994-10-05 |
1999-04-27 |
Antex Biologics, Inc. |
Vaccines comprising enhanced antigenic helicobacter spp.
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
DE851925T1
(de)
|
1995-09-21 |
2003-08-14 |
Genentech Inc., San Francisco |
Varianten des menschlichen wachstumshormons
|
|
WO2002008284A2
(en)
|
2000-07-20 |
2002-01-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
WO2002000690A2
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
WO1999040100A1
(en)
|
1998-02-09 |
1999-08-12 |
Human Genome Sciences, Inc. |
45 human secreted proteins
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
US6472520B2
(en)
|
1997-03-21 |
2002-10-29 |
The Trustees Of Columbia University In The City Of New York |
Rat PEG-3 promoter
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
|
EP1012184B1
(en)
|
1997-07-14 |
2007-10-10 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
|
US6410708B1
(en)
|
1997-11-21 |
2002-06-25 |
Genentech, Inc. |
Nucleic acids encoding A-33 related antigen polypeptides
|
|
US6333034B1
(en)
|
1997-08-26 |
2001-12-25 |
Gliatech, Inc. |
Process for inhibiting complement activation via the alternative pathway
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US8007798B2
(en)
|
1997-11-21 |
2011-08-30 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
|
US7282565B2
(en)
|
1998-03-20 |
2007-10-16 |
Genentech, Inc. |
PRO362 polypeptides
|
|
ES2305608T3
(es)
|
1997-11-21 |
2008-11-01 |
Genentech, Inc. |
Antigenos tipo a-33 y sus utilizaciones farmacologicas.
|
|
US7419663B2
(en)
|
1998-03-20 |
2008-09-02 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
|
DE69939813D1
(de)
|
1998-02-20 |
2008-12-11 |
Tanox Inc |
Inhibitoren der komplement-aktivierung
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
DK1490386T3
(da)
|
1998-03-10 |
2008-12-15 |
Genentech Inc |
Nyt polypeptid og nukleinsyrer kodende for dette
|
|
CA2340794A1
(en)
|
1998-08-27 |
2000-03-09 |
Incyte Pharmaceuticals, Inc. |
Protein transport-associated molecules
|
|
US6376653B1
(en)
|
1998-09-28 |
2002-04-23 |
Smithkline Beecham Plc |
Tie2 antagonist antibodies
|
|
CA2348757A1
(en)
|
1998-12-16 |
2000-06-22 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
JP3993746B2
(ja)
|
1998-12-22 |
2007-10-17 |
ジェネンテック・インコーポレーテッド |
腫瘍性細胞成長阻害のための組成物及び方法
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
KR20010103046A
(ko)
|
1999-03-08 |
2001-11-17 |
제넨테크, 인크. |
면역 관련 질환 치료용 조성물 및 치료 방법
|
|
CN1637019A
(zh)
|
1999-03-11 |
2005-07-13 |
Rmf迪克塔吉恩有限公司 |
血管粘着分子及其功能的调节
|
|
US6642353B1
(en)
|
1999-03-17 |
2003-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Peptide ligands for the erythropoietin receptor
|
|
AU2883900A
(en)
|
1999-07-07 |
2001-01-30 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
AU1604401A
(en)
|
1999-11-19 |
2001-05-30 |
Human Genome Sciences, Inc. |
18 human secreted proteins
|
|
EP1686134A3
(en)
|
1999-12-01 |
2006-08-09 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP1253946A2
(en)
|
2000-02-10 |
2002-11-06 |
Alexion Pharmaceuticals, Inc. |
Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
|
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
|
ATE435873T1
(de)
|
2000-03-23 |
2009-07-15 |
Genentech Inc |
Anti-c2/c2a inhibitoren zur komplement aktivierung
|
|
EP2026073B1
(en)
|
2000-04-29 |
2016-03-30 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
|
AU2001296594A1
(en)
|
2000-10-10 |
2002-04-22 |
Tanox, Inc. |
Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
|
IL155002A0
(en)
|
2000-10-12 |
2003-10-31 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
|
AR035352A1
(es)
|
2000-10-13 |
2004-05-12 |
Biogen Inc |
Anticuerpos anti-lt-beta-r humanizados
|
|
KR20030074693A
(ko)
|
2000-12-28 |
2003-09-19 |
알투스 바이올로직스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
|
US20040077575A1
(en)
|
2002-01-11 |
2004-04-22 |
Giordano Giovan Giacomo |
Inhibition of pathological angiogenesis in vivo
|
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
|
US7432356B2
(en)
|
2001-08-17 |
2008-10-07 |
Genentech, Inc. |
Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
|
|
EP2348043A1
(en)
|
2001-10-02 |
2011-07-27 |
Genentech, Inc. |
APO-2 ligand variants and uses thereof
|
|
US20060141561A1
(en)
|
2002-06-24 |
2006-06-29 |
Kelley Robert F |
Apo-2 ligand/trail variants and uses thereof
|
|
CA2494104A1
(en)
|
2002-07-31 |
2004-04-22 |
Seattle Genetics, Inc. |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
AR040778A1
(es)
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
|
|
US20040152105A1
(en)
|
2002-09-06 |
2004-08-05 |
Cytos Biotechnology Ag. |
Immune modulatory compounds and methods
|
|
US7595430B2
(en)
|
2002-10-30 |
2009-09-29 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
|
US7816497B2
(en)
|
2002-10-30 |
2010-10-19 |
University Of Kentucky |
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
|
|
WO2004075837A2
(en)
|
2003-02-21 |
2004-09-10 |
Tanox, Inc. |
Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
|
|
RU2232991C1
(ru)
|
2003-04-09 |
2004-07-20 |
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" |
Способ определения функциональной активности фактора d комплемента человека
|
|
KR100512483B1
(ko)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
EP2267028A3
(en)
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
Dual specific single domain antibodies (dAb) conjugated to PEG
|
|
DK1639011T3
(da)
*
|
2003-06-30 |
2009-02-16 |
Domantis Ltd |
Pegylerede enkelt-domæne antistoffer (dAb)
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US7923010B2
(en)
|
2003-09-11 |
2011-04-12 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
|
US20090087854A1
(en)
|
2007-09-27 |
2009-04-02 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7127355B2
(en)
|
2004-03-05 |
2006-10-24 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
WO2006062716A2
(en)
|
2004-11-18 |
2006-06-15 |
Yale University |
Methods and compositions for treating ocular disorders
|
|
WO2006071856A2
(en)
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
|
EP1833994A4
(en)
|
2005-01-04 |
2009-09-02 |
Hitachi Chemical Co Ltd |
ROLLING CIRCLE GAINING OF A PRIMER GENERATION
|
|
EP2357257B1
(en)
|
2005-02-14 |
2019-07-31 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
|
AU2006254979B2
(en)
|
2005-06-08 |
2011-11-24 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
|
|
JP5345849B2
(ja)
|
2005-10-08 |
2013-11-20 |
ポテンシア ファーマシューティカルズ, インコーポレイテッド |
眼の障害のためのコンプスタチンおよびそのアナログ
|
|
ES2551202T5
(es)
|
2005-11-04 |
2018-11-30 |
Genentech, Inc. |
Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
|
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
US20080146501A1
(en)
|
2006-02-13 |
2008-06-19 |
University Of Iowa Research Foundation |
Protective complement proteins and age-related macular degeneration
|
|
WO2007113226A1
(en)
|
2006-03-31 |
2007-10-11 |
Novartis Ag |
Organic compounds
|
|
SI2944306T1
(sl)
|
2006-06-16 |
2021-04-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
KR20090060453A
(ko)
*
|
2006-09-25 |
2009-06-12 |
메디뮨 엘엘씨 |
안정화된 항체 제제 및 그것의 용도
|
|
CN106084054A
(zh)
|
2006-11-02 |
2016-11-09 |
健泰科生物技术公司 |
人源化的抗‑d因子抗体
|
|
CA2705500A1
(en)
|
2007-05-11 |
2008-11-20 |
Tufts Medical Center |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
AR066660A1
(es)
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
|
CN101796072B
(zh)
*
|
2007-05-24 |
2014-09-24 |
埃博灵克斯股份有限公司 |
用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
|
|
US20090203001A1
(en)
|
2007-08-24 |
2009-08-13 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
EP2283163B1
(en)
|
2008-04-18 |
2015-07-08 |
Tufts Medical Center |
Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
|
|
CR20170001A
(es)
*
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
WO2009134709A2
(en)
|
2008-04-28 |
2009-11-05 |
Tufts Medical Center |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
CN101724144A
(zh)
|
2008-11-03 |
2010-06-09 |
北京键凯科技有限公司 |
新型的多臂聚乙二醇及其制备方法和应用
|
|
CN103333952B
(zh)
|
2008-11-05 |
2015-07-29 |
健泰科生物技术公司 |
年龄相关的黄斑变性中的遗传多态性
|
|
US20120115925A1
(en)
|
2008-12-23 |
2012-05-10 |
Massachusetts Eye And Ear Infirmary |
Allelic Variants Associated with Advanced Age-Related Macular Degeneration
|
|
AU2009333100B2
(en)
|
2009-01-02 |
2014-08-14 |
Alcon Research, Ltd. |
In-situ refillable ophthalmic implant
|
|
WO2010085542A2
(en)
|
2009-01-23 |
2010-07-29 |
Novartis Ag |
Biomarkers related to age-related macular degeneration (amd)
|
|
CA3045436C
(en)
|
2009-01-29 |
2025-10-07 |
Forsight Vision4 Inc |
Posterior segment drug delivery
|
|
WO2010132459A2
(en)
|
2009-05-11 |
2010-11-18 |
Cleveland Clinic Foundation |
Biomarkers for assessment of age-related macular degeneration
|
|
PT2449121T
(pt)
|
2009-07-02 |
2020-09-21 |
Lanzatech New Zealand Ltd |
Processo de produção de álcool
|
|
EP2963128A1
(en)
|
2009-07-10 |
2016-01-06 |
The Regents of the University of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
WO2011017229A2
(en)
|
2009-08-06 |
2011-02-10 |
Tufts - New England Medical Center |
Plasma complement components as expression markers for age-related macular degeneration and related phenotypes
|
|
WO2011019951A1
(en)
|
2009-08-12 |
2011-02-17 |
Pure Bioscience |
Formulations and methods employing anhydrous disinfectant
|
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
|
PH12012500924A1
(en)
*
|
2009-11-19 |
2012-11-26 |
Merck Serono Sa |
Humanized antibodies against human il-22ra
|
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
|
CN102108119A
(zh)
|
2009-12-25 |
2011-06-29 |
天津键凯科技有限公司 |
多臂聚乙二醇衍生物及其与药物的结合物和凝胶
|
|
CN103476429B
(zh)
*
|
2010-09-03 |
2016-08-24 |
施特姆森特克斯股份有限公司 |
新型调节剂及使用方法
|
|
PL2635704T3
(pl)
|
2010-11-01 |
2017-09-29 |
F.Hoffmann-La Roche Ag |
Przewidywanie progresji do zaawansowanego zwyrodnienia plamki żółtej związanego z wiekiem z zastosowaniem wskaźnika poligenicznego
|
|
JP5908972B2
(ja)
*
|
2011-04-07 |
2016-04-26 |
アムジエン・インコーポレーテツド |
新規な抗原結合タンパク質
|
|
PE20141562A1
(es)
|
2011-10-14 |
2014-11-12 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
|
JP6051998B2
(ja)
|
2012-03-30 |
2016-12-27 |
日油株式会社 |
マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
|
|
KR20160006168A
(ko)
*
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
CR20160132A
(es)
|
2013-08-12 |
2016-08-25 |
Genentech Inc |
Composiciones y método para tratar condiciones asociadas con el complemento
|
|
JP6580570B2
(ja)
|
2013-09-06 |
2019-09-25 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗体安定性を向上させるための方法
|
|
AR099625A1
(es)
*
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
SG11201608868PA
(en)
*
|
2014-05-01 |
2016-11-29 |
Genentech Inc |
Anti-factor d antibody variants and uses thereof
|
|
EP3368682B1
(en)
|
2015-10-30 |
2019-12-11 |
H. Hoffnabb-La Roche Ag |
Methods of measuring factor d activity and potency of factor d inhibitors
|
|
EP3368074A2
(en)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-factor d antibodies and conjugates
|
|
HK1257426A1
(zh)
|
2015-10-30 |
2019-10-18 |
豪夫迈‧罗氏有限公司 |
抗-因子d抗体制剂
|
|
EP3368090A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody variant conjugates and uses thereof
|